All terms in DRUGBANK

Label Id Description
Ascorbyl phosphate DB11352 [Ascorbyl phosphate is a synthetic form of Vitamin C and is found in different salt forms such as magnesium ascorbyl phosphate and sodium ascorbyl phosphate. These salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% [A27211]. As vitamin C is susceptible to breakdown of compound and discoloration in cosmetic formulations, ascorbyl phosphate, along with other Vitamin C derivatives, acts as an active and stable precursor of vitamin C that is readily absorbed into the skin with a hydrating effect on the skin [A27212]. While ascorbyl phosphate salts provide a constant delivery of vitamin C into the skin, they also mediate an antioxidant action to act as a free radical scavenger and increases collagen production *in vitro* [A27212].]
PHA-793887 DB12686 [PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.]
Vesatolimod DB12687 [Vesatolimod has been used in trials studying the treatment of Hepatitis B and Chronic Hepatitis B.]
Moxetumomab Pasudotox DB12688 [CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion.[A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.[A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568]]
Cocamidopropyl betaine DB11350 [Cocamidopropyl betaine is a mixture of closely related organic compounds derived from coconut oil and dimethylaminopropylamine that typically acts as an amphoteric surfactant in cosmetics and personal care products. It is a zwitterionic ammonium compound and fatty acid amide that contains a long hydrocarbon chain and a polar group at each end. Cocamidopropyl betaine is used as a foam booster in shampoos, emulsifying agent, thickener, antistatic agent and rarely an antiseptic agent. Impurities formed during the manufacturing process are thought to increase the prevalence of contact sensitization and mild skin irritations.]
Linseed oil DB11357 [Linseed oil is a rich source of α-Linolenic acid extracted from the dried, ripened seeds of the flax plant *Linum usitatissimum*. Other fatty acids contained in linseed oil include palmitic acid, stearic acid, oleic acid and linolenic acid. Linseed oil is particularly susceptible to polymerization reactions upon exposure to oxygen in air due to a high content of di- and triunsaturated esters. It is used in drying processes, and is used in other industrial and commercial applications. It is an indirect additive used in food contact substances.]
Salirasib DB12681 [Salirasib has been used in trials studying the diagnostic of Carcinoma, Non-Small-Cell Lung.]
Polyquaternium-10 (400 cps at 2%) DB11356 [Polyquaternium-10 is a quaternized hydroxyethyl cellulose and a polycationic polymer. It is commonly found in cosmetics and personal care products to mainly reduce static electricity and form films.]
Mubritinib DB12682 [Mubritinib has been used in trials studying the treatment of Lung Neoplasm, Renal Neoplasm, Breast Neoplasm, Ovarian Neoplasm, and Pancreatic Neoplasm.]
Propolis wax DB11355 [Propolis wax is naturally produced by honeybees by mixing the resin or exudate collected from tree buds, sap flows, or other botanical sources with beeswax that contains fatty acids and bee enzymes. Propolis itself contains various chemical compounds including flavonoids, terpenoids, aldehydes, aromatic acids, aliphatic alcohols and ethers, amino acids, and sugars. It is often found in topical formulations used to soothe minor skin irritations.]
Lumretuzumab DB12683 [Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.]
Aviscumine DB12684 [Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).]
Intepirdine DB12680 [Intepirdine has been used in trials studying the treatment of Alzheimer's Disease.]
Miltefosine DB09031 [Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and is only indicated in patients aged 12 years or older. The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.]
Vorapaxar DB09030 [Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.]
Vedolizumab DB09033 [Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation. It is used in the treatment of moderate to severe active ulcerative colitis and Crohn's disease for patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies. By blocking its primary target, α4β7 integrin, vedolizumab reduces inflammation in the gut. Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.]
Nivolumab DB09035 [Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This molecule was produced entirely on mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.[A35203] It is developed by Bristol Myers Squibb and originally FDA approved on December 22, 2014. Since this approval, nivolumab has been approved for a variety of other uses related to cancer therapy. On 2017, was notably approved for the treatment of hepatocellular carcinoma[L3632] and on July 11, 2018, the FDA approved this agent in combination with low doses of [ipilimumab] for the treatment of MSI-H/dMMR metastatic colorectal cancer.[L3611]]
Suvorexant DB09034 [Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.]
Pembrolizumab DB09037 [Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation.[A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds.[F136] It was developed by Merck & Co and firstly approved for the treatment of metastatic malignant melanoma. This is the first approved therapy against PD-1.[A7624] It was approved firstly by the FDA on September 4, 2014.[L2954] Its approval in melanoma was extended to several countries such as Australia, Israel, Korea, Macau, the European Union and the United Arab Emirates.[A33350] On June 12, 2018, Pembrolizumab was approved for the treatment of cervical cancer under the status of accelerated approval.[L2955]]
Siltuximab DB09036 [Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.]